The People's Daily health client noted that in the past half a month, there have been a number of acquisitions in the pharmaceutical field, involving Boteng Shares, Haoyuan Pharmaceutical, Jiuqiang Biology, Jianzhijia, ordinary people and other enterprises. It is worth mentioning that at present, in addition to the domestic pharmaceutical companies in the acceleration of mergers and acquisitions, there are also recent developments abroad, and mergers and acquisitions in the pharmaceutical industry may become a hot trend.
Boteng plans to acquire all the equity of Kaihui Pharmaceutical for 266 million yuan to expand the production capacity of CRO business
On the evening of March 9, Boteng issued an announcement: In order to match the rapidly growing pre-clinical and early clinical (CRO) business development needs, the company intends to acquire 100% of the equity of Kaihui Pharmaceutical held by Ruizhi Chemical for 266 million yuan in cash.
Kaihui Pharmaceutical is a wholly-owned secondary subsidiary of Wisdom Pharmaceuticals and a global small molecule drug development and production service provider. After the completion of this transaction, Boteng will hold 100% of the equity of Kaihui Pharmaceutical. Kaihui Pharmaceutical will become a wholly-owned subsidiary of the Company and will be included in the scope of the Company's consolidated financial statements.
Microsoft acquired Nuance for nearly $20 billion
On March 7, Microsoft announced the completion of its acquisition of Nuance at a cost of about $19.7 billion. Nuance is a company that provides conversational AI and cloud-based environmental clinical intelligence services to healthcare organizations.
According to Microsoft's official website
Some industry insiders pointed out that this is one of the largest mergers and acquisitions of Microsoft in the past 5 years, showing its determination to accelerate the application of artificial intelligence in the medical and health industry. It is understood that Microsoft announced the acquisition of Nuance in April 2021, and the two companies said they would jointly create the future of artificial intelligence. With its help, healthcare professionals will be able to spend less time documenting and more with patients, using the power of AI together to help organizations across industries create frictionless, personalized customer experiences.
The people intend to acquire 71.96% of the equity of Huairen Health
On March 6, the people issued an announcement that they would terminate the acquisition of 51% of the equity of Hebei Huatuo Pharmacy Pharmaceutical Chain Co., Ltd.; intend to acquire 71.9643% of the equity of Hunan Huairen Great Health Industry Development Co., Ltd., with an overall valuation of 2.275 billion yuan for the target company, and the transaction may form a new goodwill of about 1.441 billion yuan.
According to the official website of the people's pharmacy
Haoyuan Pharmaceutical intends to acquire 100% equity interest in Pharmaceutical Source Pharmaceutical
On the evening of March 4, Haoyuan Pharmaceutical announced that it intends to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli and Ningbo Jiusheng to purchase 100% of the equity of Yaoyuan Pharmaceutical held by it, and the transaction price is expected to not exceed 420 million yuan.
Through this transaction, the main business of Haoyuan Pharmaceutical will be further extended to the field of preparations, and a CRO/CDMO/CMO industrial service platform integrating "intermediates-APIs-preparations" will be created to provide customers with more comprehensive comprehensive services and enhance the competitiveness of the industry.
Jianzhijia intends to acquire 80%-100% of the equity of Tang ren Pharmaceutical
On the evening of February 28, Jianzhijia issued an announcement that the company intends to acquire 80%-100% of the equity of Tangren Pharmaceutical held by the shareholders of Tangren Pharmaceutical after the reorganization by paying cash, so as to achieve the purpose of controlling or wholly controlling Tangren Pharmaceutical, so as to realize the merger and acquisition of The Tangren Pharmaceutical chain pharmacy brand and directly operated stores, various operating assets, operating resources and their operating rights and interests, and promote the company's business expansion in the Bohai Rim region with Beijing-Tianjin-Hebei as the core.
Jiuqiang Bio intends to acquire 75% of the equity of Huihai Pharmaceutical
On February 25, Jiuqiang Bio issued an announcement that the company signed the "Investment Agreement on Wuhan Huihai Pharmaceutical Technology Development Co., Ltd." with Huihai Pharmaceutical and its shareholders Xia Zhihui and Wang Ying, agreeing to transfer 75% of the equity of Huihai Pharmaceutical held by Xia Zhihui and Wang Ying for RMB 4 million. The transaction was funded by the Company's own funds.
According to the announcement, Huihai Pharmaceutical is mainly engaged in in vitro diagnostic business, and its core business is the research and development and registration of new crown antigen testing products. Based on the leading and professional nature of Huihai Pharmaceutical in the field of new crown antigen testing, this acquisition can accelerate the registration of jiuqiang biological new crown antigen testing products, expand the company's product line, and further enhance the competitiveness and comprehensive strength of its testing business.
Editor-in-charge: Liu Yingqi